(VIANEWS) - Astrazeneca (AZN), United Microelectronics (UMC), UFP Industries (UFPI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Astrazeneca (AZN)
43% sales growth and 25.67% return on equity
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.
Astrazeneca's sales growth this year is expected to be 35.1% and 15.7% for next year.
Year-on-year quarterly revenue growth grew by 31%, now sitting on 29.53B for the twelve trailing months.
Volume
Today's last reported volume for Astrazeneca is 6376840 which is 37.47% below its average volume of 10198500.
Astrazeneca's sales growth for the next quarter is 43%. The company's growth estimates for the present quarter and the next is 40.4% and 45.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.67%.
Volatility
Astrazeneca's last day, last week, and last month's current volatility was 1.29%, 0.82%, and 0.76%, respectively.
Astrazeneca's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.04% (day), 0.89% (last week), and 1.18% (last month), respectively.
Astrazeneca's Stock Yearly Top and Bottom Value
Astrazeneca's stock is valued at $58.74 at 01:22 EST, below its 52-week high of $60.93 and way above its 52-week low of $46.48.
Astrazeneca's Moving Average
Astrazeneca's value is higher than its 50-day moving average of $57.85 and higher than its 200-day moving average of $55.50.2. United Microelectronics (UMC)
26.5% sales growth and 15.72% return on equity
United Microelectronics Corporation operates as a semiconductor wafer foundry in Taiwan, Singapore, China, Hong Kong, Japan, the United States, Europe, and internationally.
United Microelectronics's sales growth this year is expected to be 20% and 41.8% for next year.
Year-on-year quarterly revenue growth grew by 14.7%, now sitting on 188.17B for the twelve trailing months.
Volume
Today's last reported volume for United Microelectronics is 5006080 which is 27.83% below its average volume of 6936770.
United Microelectronics's sales growth is a negative 0% for the current quarter and 26.5% for the next. The company's growth estimates for the ongoing quarter and the next is 260% and 18.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.72%.
Volatility
United Microelectronics's last day, last week, and last month's current volatility was 0.29%, 1.57%, and 2.44%, respectively.
United Microelectronics's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.28% (day), 2.65% (last week), and 2.62% (last month), respectively.
United Microelectronics's Stock Yearly Top and Bottom Value
United Microelectronics's stock is valued at $11.74 at 01:22 EST, below its 52-week high of $12.62 and way above its 52-week low of $4.20.
United Microelectronics's Moving Average
United Microelectronics's worth is higher than its 50-day moving average of $11.28 and way above its 200-day moving average of $9.78.3. UFP Industries (UFPI)
16.2% sales growth and 27.31% return on equity
UFP Industries, Inc., through its subsidiaries, designs, manufactures, and markets wood and wood-alternative products in North America, Europe, Asia, and Australia.
UFP Industries's sales growth this year is expected to be 54.6% and a negative 7.1% for next year.
Year-on-year quarterly revenue growth grew by 117.4%, now sitting on 7.41B for the twelve trailing months.
Volume
Today's last reported volume for UFP Industries is 102422 which is 59.22% below its average volume of 251201.
UFP Industries's sales growth for the next quarter is 16.2%. The company's growth estimates for the ongoing quarter and the next is 24% and 9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.31%.
Volatility
UFP Industries's last day, last week, and last month's current volatility was 0.62%, 1.33%, and 1.30%, respectively.
UFP Industries's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.43% (day), 2.18% (last week), and 2.19% (last month), respectively.
UFP Industries's Stock Yearly Top and Bottom Value
UFP Industries's stock is valued at $68.15 at 01:22 EST, way under its 52-week high of $89.97 and way higher than its 52-week low of $48.82.
UFP Industries's Moving Average
UFP Industries's worth is under its 50-day moving average of $73.57 and under its 200-day moving average of $75.34.4. Stryker Corp (SYK)
12.8% sales growth and 15.68% return on equity
Stryker Corporation operates as a medical technology company.
Stryker Corp's sales growth this year is expected to be 20.6% and 7.3% for next year.
Year-on-year quarterly revenue growth grew by 55.4%, now sitting on 16.25B for the twelve trailing months.
Volume
Today's last reported volume for Stryker Corp is 945702 which is 19.99% below its average volume of 1182080.
Stryker Corp's sales growth for the next quarter is 12.8%. The company's growth estimates for the current quarter and the next is 8.4% and 1.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.68%.
Volatility
Stryker Corp's last day, last week, and last month's current volatility was 1.52%, 1.11%, and 1.08%, respectively.
Stryker Corp's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.73% (day), 1.57% (last week), and 1.82% (last month), respectively.
Stryker Corp's Stock Yearly Top and Bottom Value
Stryker Corp's stock is valued at $271.65 at 01:22 EST, under its 52-week high of $281.16 and way higher than its 52-week low of $196.09.
Stryker Corp's Moving Average
Stryker Corp's worth is higher than its 50-day moving average of $269.40 and higher than its 200-day moving average of $257.93.5. Royalty Pharma (RPRX)
6.2% sales growth and 19.76% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma's sales growth this year is expected to be 5.6% and 3.5% for next year.
Year-on-year quarterly revenue growth grew by 8.6%, now sitting on 2.24B for the twelve trailing months.
Volume
Today's last reported volume for Royalty Pharma is 1276310 which is 50.94% below its average volume of 2602030.
Royalty Pharma's sales growth for the next quarter is 6.2%. The company's growth estimates for the ongoing quarter and the next is 41.7% and 171.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.76%.
Royalty Pharma's Stock Yearly Top and Bottom Value
Royalty Pharma's stock is valued at $36.29 at 01:22 EST, way below its 52-week high of $53.23 and above its 52-week low of $34.80.
Royalty Pharma's Moving Average
Royalty Pharma's value is below its 50-day moving average of $38.28 and way below its 200-day moving average of $41.49.Previous days news about Royalty Pharma(RPRX)
- According to Bloomberg Quint on Thursday, 23 September, "Last year, King's former co-head, Jennifer Fox, left for Nuvation Bio Inc. while Chris Hite, who had been Citi's global head of the health-care group for 12 years, went to Royalty Pharma Plc."